Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies

Keyphrases

• Venous Thromboembolism Prevention 100%
• Rivaroxaban 100%
• Pooled Analysis 100%
• Hip or Knee Arthroplasty 100%
• Enoxaparin 83%
• All-cause Mortality 66%
• Recurrent Venous Thromboembolism 66%
• Bleeding 50%
• Treatment Duration 33%
• Once-daily 33%
• Bleeding Events 33%
• Efficacy Endpoint 33%
• Active Treatment 16%
• Major Bleeding 16%
• Non-majors 16%
• Clinically Significant 16%
• Phase II Study 16%
• Subgroup Analysis 16%
• Serious Adverse Events 16%
• Creatinine Clearance 16%
• Mortality Event 16%
• Patient Subgroups 16%
• Liver Safety 16%
• Total Hip or Knee Arthroplasty 16%
• Four-phase 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Venous Thromboembolism 100%
• Rivaroxaban 100%
• Enoxaparin 83%
• Bleeding 66%
• All Cause Mortality 66%
• Adverse Event 16%
• Creatinine 16%